PHVS Pharvaris N.V.

Note: The stock trades discussed in this article come from AI Finance Labs, an investment experiment that operates publicly viewable portfolios directed by models including Claude, ChatGPT, Grok and DeepSeek. Anthropic’s Claude AI recently sold its positions in Ardelyx Inc. (NASDAQ: ARDX) and Aris Mining Corp. (NYSE: ARIS) and replaced them with Syndax Pharmaceuticals Inc. […]

Pharvaris (NasdaqGS:PHVS) reported positive topline data from its CHAPTER-3 pivotal Phase 3 trial of deucrictibant XR for hereditary angioedema prevention. The study met all primary and secondary endpoints with statistical significance, supporting deucrictibant XR as a potential prophylactic treatment option. Management plans to use CHAPTER-3 data in upcoming marketing authorization applications for deucrictibant XR in hereditary angioedema. The statistically significant CHAPTER-3 outcome...

BioCryst Pharmaceuticals (NASDAQ:BCRX) is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley event. Gayer, who became CEO on Jan. 1, said

Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.

Pharvaris N.V. (NASDAQ:PHVS) reported on September 8 that once-daily deucrictibant extended-release tablets reduced hereditary angioedema attack rates by 83% relative to placebo in the Phase 3 CHAPTER-3 trial. The result was statistically significant, with a 95% confidence interval of 72% to 90% and a p-value below 0.0001. The global, double-blind study randomized 85 participants to […]

RBC Capital said it expects revenue tailwinds for BioCryst’s Orladeyo drug after Pharvaris posted strong Phase 3 data for HAE therapy.

BioCryst Pharmaceuticals' (BCRX) Ordaleyo faces competitive pressure in the hereditary angioedema tr

Pharvaris (PHVS) could gain greater market share in hereditary angioedema with its deucrictibant ext

The company will seek approval for deucrictibant XR as competition in the HAE market mounts.

Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients.

Biotech stocks Roivant and Pharvaris hit records Tuesday on "blowout" and "bull case" results for lung and swelling disease treatments.

Roivant Sciences reported positive Phase 2 results for its experimental lung disease drug, Mosliciguat, while Pharvaris’ oral therapy met the main goal of a Phase 3 study of preventive treatment for hereditary angioedema.

Roivant Sciences (ROIV) shares soared 19% after the company said its Pulmovant unit's phase 2 PHocus

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively tr

Pharvaris (NASDAQ:PHVS) shares jumped 27% on Tuesday after the company reported positive topline results from its pivotal Phase 3 CHAPTER-3 study evaluating deucrictibant XR for the prevention of hereditary angioedema attacks. The study met its primary endpoint, with once-daily deucrictibant XR producing an 83% reduction in the HAE attack rate compared with placebo.

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

Pharvaris (PHVS) remains well-positioned ahead of results from its phase 3 CHAPTER-3 trial of deucri

Note: the trade details cited in this article come from The Claude Portfolio account on X, a third-party account not affiliated with Anthropic. It tracks how different AI models would trade if given a live portfolio. Claude AI recently added two names that couldn’t be more different. One is a small biotech with one drug […]

Pharvaris stock has delivered a strong 103.0% return over the past five years, yet the latest valuation checks and market multiples suggest the shares may now sit on the expensive side rather than offering clear value. Over the last 5 years Pharvaris has returned 103.0%, which sets a high bar for any further upside to be justified by fundamentals. Future growth in revenue and cash flow can support the current price, but execution risk around turning that growth into sustainable profitability...

The consensus price target hints at a 43% upside potential for Pharvaris (PHVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

This late-stage biotech innovator in rare disease therapies reported significant insider selling amid strong one-year share price gains.

Does Pharvaris N.V. (PHVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

IBM downgraded, Cava upgraded: Wall Street's top analyst calls

The mean of analysts' price targets for Pharvaris (PHVS) points to a 36.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Pharvaris stock jumped early Monday, but closed down, after the FDA agreed to review the company's treatment for a serious swelling disease.